Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 37

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 37
---
 ​ | AUDITMATTERS | ​ | ​ | EXECUTIVEOFFICERS | ​ | ​ | EXECUTIVECOMPENSATION | ​ | ​ | STOCKOWNERSHIPINFORMATION | ​ | ​ | INFORMATIONABOUT THEANNUALMEETING ANDVOTING | ​ | ​ | ADDITIONALINFORMATION | ​ | ​ | APPENDIX A | ​ | ​ | APPENDIX B | ​ |

TABLE OF CONTENTS Executive Compensation

| ​ | ​ | EXECUTIVE COMPENSATION | ​ |

| ​ |                                                 | ​ | ​ | PROPOSAL 3 | ​ |
| ​ | Advisory Vote to Approve Executive Compensation | ​ |   |            |   |

| ​ |     | ​ | ​ | The board unanimously recommends votingFORthe advisory vote to approve the compensation of our named executive officers. | ​ |

**As required by Section 14A of the Exchange Act, we are asking stockholders to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement. This proposal, commonly known as a “say on pay” proposal, gives stockholders the opportunity to approve or reject our executive pay program through the following resolution: “RESOLVED, that the stockholders approve, on an advisory basis, the compensation of the named executive officers of Pacira BioSciences, Inc., as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and related narrative discussion in the Company’s proxy statement.” We currently conduct the say on pay advisory vote annually, with the next vote following this year’s vote occurring at the next annual meeting of stockholders: (see Proposal 4, relating to the advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers). The say on pay vote is advisory and therefore will not be binding on the People & Compensation Committee, the board, or the Company. However, the People & Compensation Committee and board will review the voting results and take them into consideration when making future decisions regarding executive compensation. Please read the “Executive Compensation” section of this proxy statement before determining how to vote on this proposal. As discussed in more detail in the “Compensation Discussion and Analysis” section, which includes our 2024 performance highlights, the primary objectives of our executive compensation program are to: • increase stockholder value by attracting and retaining talented executives; • rewarding performance that meets or exceeds our established goals; and • aligning the interests of our